Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL).

Marine Gross-Goupil,Aude Flechon,Christine Chevreau,Delphine Topart,Gwenaelle Gravis,Stéphane Oudard,Jean-Marc Tourani,Lionnel Geoffrois,Emeline Meriaux,Antoine Thiery-Vuillemin,Philippe Barthélémy,Sylvain Ladoire,Brigitte Laguerre,Valérie Perrot,Anais Billard,Bernard Escudier,Laurence Albiges

Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL).

2020

Marine Gross-Goupil
Aude Flechon
Christine Chevreau
Delphine Topart
Gwenaelle Gravis
Stéphane Oudard
Jean-Marc Tourani
Lionnel Geoffrois
Emeline Meriaux
Antoine Thiery-Vuillemin
Philippe Barthélémy
Sylvain Ladoire
Brigitte Laguerre
Valérie Perrot
Anais Billard
Bernard Escudier
Laurence Albiges

683Background: Cabozantinib (Cabo) is approved in Europe for the treatment of mRCC in first line and after failure of tyrosine kinase inhibitors (TKI). We report the results from real-world use of ...

Keywords:

Pathology
Oncology
Refractory
Cabozantinib
VEGF receptors
Internal medicine
Renal cell carcinoma
Medicine
Tyrosine kinase
in patient
first line
real world data

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations